According to the Futu Securities app, Junshi Bio (01877) rose more than 3% in the morning session, as of the time of publication, it rose 2.39% to HK$6.47, with a turnover of 6.6765 million Hong Kong dollars.

On the news front, Junshi Bio announced that recently, the company signed a "License Agreement" with the licensor. According to the License Agreement, the licensor grants the company the exclusive license rights and sublicenses in the Greater China region (including mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan region) to develop, manufacture, use, import, export, sell, and commercialize two dual-target fusion proteins, while the company and the licensor equally share ownership rights to develop, manufacture, use, import, export, sell, and commercialize one of the licensed products globally on a 50%:50% equity basis. The company will make corresponding upfront payments, milestone payments, and sales royalties to the licensor based on project progress, while the licensor may pay the company sublicense income outside of Greater China.

The subject of this transaction consists of two dual-target fusion proteins (i.e., License Product 1 and License Product 2), mainly used for malignant tumor treatment. Currently, License Product 1 is in Phase I clinical trials overseas, and the company has submitted an application for Phase I clinical trials of License Product 1 domestically to the National Medical Products Administration. License Product 2 is in the preclinical research stage. The announcement stated that the signing of this License Agreement is in line with the company's overall development strategy, conducive to enriching the company's R&D pipeline, improving the company's market layout, providing treatment options for clinical needs that have not yet been met by the market, and will have a positive impact on the company's ongoing operations.